JP2008539795A - キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法 - Google Patents

キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法 Download PDF

Info

Publication number
JP2008539795A
JP2008539795A JP2008512587A JP2008512587A JP2008539795A JP 2008539795 A JP2008539795 A JP 2008539795A JP 2008512587 A JP2008512587 A JP 2008512587A JP 2008512587 A JP2008512587 A JP 2008512587A JP 2008539795 A JP2008539795 A JP 2008539795A
Authority
JP
Japan
Prior art keywords
ephrin
cupredoxin
cancer
peptide
azurin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008512587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539795A5 (enExample
Inventor
チャクラバーティ、アナンダ
ダス・グプタ、タパス
亨 山田
チャウダリ、アニタ
フィアロー、アルセニオ
ジュ、ヨンフア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2008539795A publication Critical patent/JP2008539795A/ja
Publication of JP2008539795A5 publication Critical patent/JP2008539795A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008512587A 2005-05-20 2006-05-19 キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法 Pending JP2008539795A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68281205P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
PCT/US2006/019684 WO2007018671A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Publications (2)

Publication Number Publication Date
JP2008539795A true JP2008539795A (ja) 2008-11-20
JP2008539795A5 JP2008539795A5 (enExample) 2009-07-02

Family

ID=37727776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008512587A Pending JP2008539795A (ja) 2005-05-20 2006-05-19 キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法

Country Status (10)

Country Link
EP (1) EP1888106A4 (enExample)
JP (1) JP2008539795A (enExample)
KR (1) KR20080040631A (enExample)
AU (1) AU2006277009A1 (enExample)
BR (1) BRPI0612424A2 (enExample)
CA (1) CA2608512A1 (enExample)
IL (1) IL187138A0 (enExample)
MX (1) MX2007014598A (enExample)
NO (1) NO20076391L (enExample)
WO (1) WO2007018671A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
EP2061498A4 (en) * 2006-09-14 2009-11-04 Univ Illinois COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES
WO2008086523A2 (en) * 2007-01-11 2008-07-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
KR101102829B1 (ko) * 2008-09-12 2012-01-05 재단법인 제주테크노파크 구멍갈파래 추출물과 그것의 항염증제로서의 용도
CN110090295B (zh) * 2018-01-29 2022-12-23 武汉康理通科技有限公司 Ephrin-B1在制备治疗炎症性肠病的药物中的用途
WO2023205752A2 (en) * 2022-04-22 2023-10-26 University Of Miami Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases
TW202547871A (zh) * 2024-03-27 2025-12-16 美商麥第爾醫療公司 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505246A (ja) * 2001-02-15 2005-02-24 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 細胞死を調節する細胞障害性因子
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505246A (ja) * 2001-02-15 2005-02-24 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 細胞死を調節する細胞障害性因子
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy

Also Published As

Publication number Publication date
BRPI0612424A2 (pt) 2009-01-27
IL187138A0 (en) 2008-02-09
AU2006277009A1 (en) 2007-02-15
NO20076391L (no) 2008-02-15
MX2007014598A (es) 2008-02-07
KR20080040631A (ko) 2008-05-08
EP1888106A2 (en) 2008-02-20
WO2007018671A3 (en) 2007-11-22
CA2608512A1 (en) 2007-02-15
EP1888106A4 (en) 2009-01-14
WO2007018671A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US10889621B2 (en) Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins
US11046733B2 (en) Compositions and methods to treat cancer with CpG rich DNA and cupredoxins
US7511117B2 (en) Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US10058585B2 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US8124055B2 (en) Compositions and methods to control angiogenesis with cupredoxins
EP1653990A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
AU2006277009A1 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
JP2008545398A (ja) キュプレドキシンおよびシトクロムｃを用いてｈｉｖ感染を治療するための組成物および方法
CN101198351A (zh) 用铜氧还蛋白治疗ephrin信号传导相关性病变的组合物和方法
WO2008086523A2 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US10266868B2 (en) Compositions for treating HIV infection with cupredoxin and cytochrome C
KR20080019615A (ko) 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
JP2009502797A (ja) 血管形成をキュプレドキシンで制御するための組成物および方法
CN101272800A (zh) 使用铜氧还蛋白控制血管发生的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120403